PBAC Public Summary Documents - July 2012

Public Summary Documents relating to the July 2012 PBAC meeting.

• Abiraterone, tablet, 250 mg (as acetate), Zytiga® - July 2012
• Aztreonam, powder for inhalation, 75 mg, with diluent, Cayston® - July 2012
• Boceprevir, capsule, 200 mg, Victrelis® - July 2012
• Botulinum toxin type a purified neurotoxin complex, lyophilised powder for injection, 100 units, Botox® (migraine) - July 2012
• Botulinum toxin type a purified neurotoxin complex, lyophilised powder for injection, 100 units, Botox® (urinary incontinence) - July 2012
• Dabigatran etexilate, capsules, 110 mg and 150 mg (as mesilate), Pradaxa® - July 2012
• Dorzolamide hydrochloride with timolol maleate, eye drops 20 mg (base)-5 mg (base) per mL (2%-0.5%), single dose units 0.6 mL, 60, Cosopt® Preservative Free Eye Drops - July 2012
• Erlotinib, tablet, 25 mg, 100 mg, 150 mg (as hydrochloride), Tarceva® - July 2012
• Ezetimibe and atorvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets atorvastatin 10 mg, 20 mg, 40 mg or 80 mg, Atozet Composite Pack® - July 2012
• Ivabradine, tablet, 5 mg and 7.5 mg (as hydrochloride), Coralan® - July 2012
• Linagliptin, tablet, 5 mg, Trajenta® - July 2012
• Methylphenidate hydrochloride, Tablets, 18 mg, 27 mg, 36 mg, and 54 mg,(extended release) Concerta® - July 2012
• Mycophenolate sodium, tablet (enteric coated), 180 mg and 360 mg (mycophenolic acid), Myfortic® - July 2012
• Plerixafor, solution for injection, 20 mg in 1 mL, 1.2 mL, Mozobil® - July 2012
• Prucalopride, tablets, 1 mg and 2 mg (as succinate), Resotrans® - July 2012
• Review of Statin Therapies - July 2012
• Rifaximin, tablet, 550 mg, Xifaxan® - July 2012
• Sapropterin, soluble tablet, 100 mg (as dihydrochloride), Kuvan® - July 2012
• Saxagliptin, tablet, 5 mg (as hydrochloride), Onglyza® - July 2012
• Strontium ranelate, sachet containing granules for oral suspension, 2g, Protos® - July 2012
• Sunitinib malate, capsule, 12.5 mg, 25 mg and 50 mg (base), Sutent® - July 2012
• Tapentadol, tablet, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg (as hydrochloride) (sustained release), Palexia SR® - July 2012
• Telaprevir, tablet, 375 mg, Incivo® - July 2012
• Trastuzumab, powder for I.V. infusion, 60 mg and 150 mg, Herceptin® - July 2012
• Vemurafenib, tablet, 240 mg, Zelboraf® - July 2012